Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis
Open Access
- 5 January 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 787498
Abstract
The induction of specific immunological tolerance represents an important therapeutic goal for multiple sclerosis and other autoimmune diseases. Sound knowledge of the target antigens, the underlying pathomechanisms of the disease and the presumed mechanisms of action of the respective tolerance-inducing approach are essential for successful translation. Furthermore, suitable tools and assays to evaluate the induction of immune tolerance are key aspects for the development of such treatments. However, investigation of the mechanisms of action underlying tolerance induction poses several challenges. The optimization of sensitive, robust methods which allow the assessment of low frequency autoreactive T cells and the long-term reduction or change of their responses, the detection of regulatory cell populations and their immune mediators, as well as the validation of specific biomarkers indicating reduction of inflammation and damage, are needed to develop tolerance-inducing approaches successfully to patients. This short review focuses on how to demonstrate mechanistic proof-of-concept in antigen-specific tolerance-inducing therapies in MS.Keywords
This publication has 141 references indexed in Scilit:
- Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE studyTransplantation Research, 2013
- In Vitro Treg Suppression Assays2011
- Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cellsJournal of Experimental Medicine, 2009
- Prospects for Antigen-Specific Tolerance Based Therapies for the Treatment of Multiple Sclerosis2009
- Therapeutic vaccination with a trivalent T‐cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosisImmunology, 2007
- Compromised CD4+ CD25high regulatory T‐cell function in patients with relapsing‐remitting multiple sclerosis is correlated with a reduced frequency of FOXP3‐positive cells and reduced FOXP3 expression at the single‐cell levelImmunology, 2007
- Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis?Journal of Virology, 2007
- Epigenetic Control of the foxp3 Locus in Regulatory T CellsPLOS Biology, 2007
- Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patientsClinical and Experimental Immunology, 2007
- Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosisJournal of Clinical Investigation, 2006